Drug intelligence / Profile preview

mescaline + ketanserin

Development stage
Unknown
Lead developer
MindMed
Modality
Small Molecules
Administration
Oral
01

Overview

Mescaline + ketanserin is a combination of two small molecule drugs. Mescaline is a naturally occurring psychedelic protoalkaloid of the substituted phenethylamine class, known for its hallucinogenic effects mediated primarily through agonism at the serotonin 5-HT2A receptor. Ketanserin is an antihypertensive agent and selective serotonin 5-HT2A receptor antagonist, also acting on α1-adrenergic and histamine H1 receptors. When administered together, ketanserin blocks or significantly attenuates the psychoactive effects of mescaline by antagonizing the 5-HT2A receptor, thereby preventing mescaline-induced altered states of consciousness[1][4][5]. This combination has been used in research to study serotonergic mechanisms underlying psychedelic experiences.

02

Targets

HRH1 (Histamine H1 Receptor)HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)ADRA1A (α1A)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on mescaline + ketanserin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mescaline + ketanserin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call